Skip to content

Svennilson Peter

Follow

13F filer, CIK 1606074, SAN FRANCISCO, CA

Svennilson Peter reported $1,225,585,000 across 7 holdings for the quarter ended 2020-09-30, in a 13F-HR filed 2020-11-04.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-20-010814

Period
2020-09-30
Reported value
$1.23B
Holdings
7
Top 10 weight
100%
New
1
Sold out
1

Stakes and trades reported after 2020-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
    Accepted , ingested
  • TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
NRIXnew+6,755,881$236M
NGM BIOPHARMACEUTICALS INCadded+310,954$4.95M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RCUSexited-1,767,676-$43.7M
RAPT THERAPEUTICS INCreduced-1,146,654-$36.9M
GRITSTONE BIO INCreduced-831,452-$2.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2020

Share positions as resolved from 13F-HR 0000950123-20-010814, largest first. % of portfolio is the value over $1,225,585,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: 15,694,091 shares; 2019Q3: 16,166,907 shares; 2019Q4: 16,420,829 shares; 2020Q1: 17,323,144 shares; 2020Q2: 17,706,978 shares; 2020Q3: 18,017,932 shares 18,017,932$287M23.39%+310,954
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: not reported; 2019Q3: not reported; 2019Q4: not reported; 2020Q1: 7,977,384 shares; 2020Q2: 7,977,384 shares; 2020Q3: 7,977,384 shares 7,977,384$278M22.65%0Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: not reported; 2019Q3: not reported; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: 6,755,881 shares 6,755,881$236M19.24%newTimeline
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: not reported; 2019Q3: not reported; 2019Q4: 6,777,151 shares; 2020Q1: 6,777,151 shares; 2020Q2: 6,777,151 shares; 2020Q3: 5,630,497 shares 5,630,497$181M14.79%-1,146,654
CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q4: 4,677,938 shares; 2019Q1: 4,677,939 shares; 2019Q2: 4,677,939 shares; 2019Q3: 6,009,702 shares; 2019Q4: 6,009,702 shares; 2020Q1: 6,051,376 shares; 2020Q2: 6,051,376 shares; 2020Q3: 6,051,376 shares 6,051,376$123M10%0
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: not reported; 2019Q3: not reported; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: 4,768,181 shares; 2020Q3: 4,768,181 shares 4,768,181$119M9.73%0Timeline
GRITSTONE BIO INCGRITSTONE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q4: 3,102,934 shares; 2019Q1: 3,102,934 shares; 2019Q2: 3,102,934 shares; 2019Q3: 3,102,934 shares; 2019Q4: 3,102,934 shares; 2020Q1: 3,102,934 shares; 2020Q2: 1,700,945 shares; 2020Q3: 869,493 shares 869,493$2.3M0.19%-831,452

Sold out in Q3 2020

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RCUSARCUS BIOSCIENCES INC1,767,676$43.7Mshares

How Q3 2020 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-20-010814 base2020-11-04acceptance time not in the bulk data set